Welcome to our dedicated page for Maravai Lifesciences Holdings news (Ticker: MRVI), a resource for investors and traders seeking the latest updates and insights on Maravai Lifesciences Holdings stock.
Maravai LifeSciences Holdings, Inc. reports recurring developments as a life sciences supplier of reagents and services for drug therapy, diagnostics, vaccine and human disease research. Company updates center on its TriLink nucleic acid synthesis business, including mRNA, oligonucleotides and CleanCap-related technologies, and its Cygnus biologics safety testing business, including host cell protein ELISA kits, impurity detection assays, reagents and services.
News about MRVI commonly covers quarterly financial results, segment revenue trends, guidance, restructuring and operating cost initiatives, investor conference participation, executive and board changes, and product or commercial updates tied to researchers, biotech innovators, vaccine developers, diagnostics companies and cell and gene therapy customers.
Maravai LifeSciences (NASDAQ: MRVI) reported third quarter 2025 results for the period ended September 30, 2025: revenue $41.6M, net loss $(45.1)M, and Adjusted EBITDA $(10.8)M. Nucleic Acid Production revenue was $25.4M (down 52.9% YoY) driven by a lack of high-volume CleanCap commercial vaccine orders, while Biologics Safety Testing revenue was $16.3M (up 7.2% YoY).
The company reiterated full-year 2025 revenue guidance of approximately $185.0M and said TriLink is expected to deliver double-digit sequential revenue growth in Q4 2025; management noted restructuring and cost-reduction initiatives are on track.
Maravai LifeSciences (NASDAQ: MRVI) will announce third quarter 2025 financial and operating results after market close on Thursday, November 6, 2025. The company will host an earnings conference call and webcast the same day at 2:00 p.m. PT / 5:00 p.m. ET.
Investors may join by phone at (800) 579-2543 or (785) 424-1789 using Conference ID: MARAVAI, or listen via live or archived webcast at https://investors.maravai.com.
Maravai LifeSciences (NASDAQ: MRVI) reported challenging Q2 2025 financial results with revenue declining 31.7% year-over-year to $47.4 million. The company posted a net loss of $(69.8) million, including a $30.4 million goodwill impairment, and negative Adjusted EBITDA of $(10.4) million.
Under new leadership with CEO Bernd Brust and CFO Raj Asarpota, Maravai announced a major restructuring targeting over $50 million in annualized cost savings through labor, facilities, and productivity initiatives. The base business excluding high-volume CleanCap grew 5%, driven by Cygnus products and Biologics Safety Testing segment growth of 9.9%.
The company has withdrawn its 2025 guidance as the new management team conducts a comprehensive business review, with expectations for Net Loss Reduction, Positive Adjusted EBITDA and Free Cash Flow by second half 2026.
Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services, has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025, after market close.
The company will host a conference call and webcast at 2:00 p.m. PT/ 5:00 p.m. ET on the same day. Investors can join via phone by dialing (800) 267-6316 or (203) 518-9783 with Conference ID MARAVAI, or access the webcast through the "Investors" section of Maravai's website.
Maravai LifeSciences (NASDAQ: MRVI) has appointed Rajesh "Raj" Asarpota as Executive Vice President and Chief Financial Officer, effective June 30, 2025. He succeeds Kevin Herde, who will transition to an advisory role to support the transition.
Asarpota brings nearly three decades of executive leadership experience, including over 10 years as CFO in life sciences and medical device companies. He will lead Maravai's global Finance, Accounting, Treasury, Investor Relations, Corporate Strategy, and Information Technology teams, focusing on driving growth and profitability in nucleic acid technologies and bioprocess impurity analytics.
This CFO transition follows the recent appointment of Bernd Brust as CEO. The company will review its full-year 2025 financial guidance during its second-quarter earnings call in August.
Maravai LifeSciences (NASDAQ: MRVI) has released its 2024 Sustainability Report, highlighting significant progress across four key areas: Product Innovation, People, Governance, and Sustainable Growth. The company launched 49 new products and completed a state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold. Notable achievements include establishing an RNA Innovation Center with Johns Hopkins University and manufacturing over 130 GMP batches for mRNA.
The company demonstrated strong employee engagement with a 95% participation rate in their annual survey and expanded their employee resource programs. In governance, they appointed R. Andrew Eckert as independent Chairman and strengthened their intellectual property position. Sustainability initiatives included enhanced greenhouse gas emissions reporting and renewable energy projects, with their Leland facility's solar panels generating over 180,000 kWh.
Maravai LifeSciences (NASDAQ: MRVI) has released its 2024 Sustainability Report, highlighting significant progress across four key areas: Product Innovation, People, Governance, and Sustainable Growth. The company launched 49 new products and completed a state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold. Notable achievements include establishing an RNA Innovation Center with Johns Hopkins University and manufacturing over 130 GMP batches for mRNA.
The report details strong employee engagement with a 95% survey participation rate and expanded employee resource initiatives. In governance, the company appointed R. Andrew Eckert as independent Chairman and strengthened its intellectual property position. Sustainability efforts included enhanced greenhouse gas emissions reporting, solar energy generation at the Leland facility, and EV charging stations that saved over 19,000 gallons of gasoline.
TriLink BioTechnologies (NASDAQ: MRVI) has launched its first mRNA synthesis kit featuring CleanCap® capping technology. The all-in-one in vitro transcription (IVT) kit delivers up to 2X more mRNA yield and up to 85% lower dsRNA compared to market alternatives. The kit includes CleanCap® AG (3′ OMe), CleanScribe™ RNA Polymerase, nucleotides with N1-methylpseuouridine, and CleanScript® IVT.
To celebrate the launch, TriLink is donating ten kits each to seven academic institutions across the U.S. and Europe, including Houston Methodist Research Institute, UC San Diego, University Medical Center Utrecht, University of Oxford, and Yale School of Medicine. The donated kits can yield up to a combined 250mg of capped mRNAs.
The kit features CleanCap AG (3′ OMe) with over 95% capping efficiency for improved protein expression, streamlining mRNA manufacturing with fewer steps compared to traditional ARCA or enzymatic methods.